Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study.
We have recently shown significant renoprotective effects with the administration of pituitary adenylate cyclase-activating polypeptide (PACAP) in models of myeloma kidney. PACAP markedly inhibited the production of proinflammatory cytokines stimulated by immunoglobulin light chains in human renal proximal tubule epithelial cells and in the kidneys of rats infused with myeloma light chains. PACAP was also shown to suppress the proliferation of human kappa and lambda light chain-secreting multiple myeloma-derived cells. In this case study, an 81-year-old male patient with active multiple myeloma and myeloma kidney was infused intravenously with synthetic human PACAP38 at a rate of 4 pmol/kg/min for 120 min. The continuous infusion increased the level of PACAP38 in blood, with a plateau at about 0.2 nM during the infusion. The level of PACAP in the blood rapidly declined after the cessation of administration with a half-life of about 5-10 min. The continuous infusion did not significantly alter the basal glucose level, blood gases or blood pressure. There was a large reduction in free lambda light chains in urine after the start of the treatment with PACAP. These studies show that PACAP can be safely used in humans and suggest that it could be used as a novel therapeutic agent for the treatment of multiple myeloma and myeloma kidney.
Li
Min
M
Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA. minlee@tulane.edu
Maderdrut
Jerome L
JL
Lertora
Juan J L
JJ
Batuman
Vecihi
V
D000369:Aged, 80 and over; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007146:Immunoglobulin lambda-Chains / Q000652:urine; D007262:Infusions, Intravenous; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D016896:Treatment Outcome
D016207:Cytokines; D007146:Immunoglobulin lambda-Chains; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide